Single Biggest Cancer Dictionary in the World

What is anti-CD19/CD3 tetravalent antibody AFM11?

Pronunciation: /ˈænˌti ˈsiˈdi ˈnaɪnˈtin ˈsiˈdi θri ˌtɛtrəˈveɪlənt ˈæntɪˌbɑdi afm* ˈilɛvən/

anti-CD19/CD3 tetravalent antibody AFM11

Definition

An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B cells and cytotoxic T lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth.